The FDA on April 7, 2021 granted regular approval to TRODELVY® for patients with unresectable locally advanced or metastatic Triple-Negative Breast Cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. TRODELVY® is a product of Immunomedics Inc.
Bottom Ad
Advertisement
Subscribe
